Carnegie Investment Counsel’s CME Group CME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$33.5M Sell
159,681
-2,797
-2% -$774K 0.67% 40
2026
Q1
$45.7M Buy
162,478
+5,282
+3% +$1.57M 0.89% 24
2025
Q4
$42.9M Buy
157,196
+1,472
+0.9% +$400K 0.79% 26
2025
Q3
$42.1M Buy
155,724
+6,939
+5% +$1.89M 0.79% 26
2025
Q2
$41M Buy
148,785
+12,350
+9% +$3.36M 0.82% 27
2025
Q1
$36M Buy
136,435
+125,087
+1,102% +$30.9M 0.86% 27
2024
Q4
$2.64M Buy
11,348
+834
+8% +$192K 0.08% 188
2024
Q3
$2.32M Buy
10,514
+957
+10% +$198K 0.07% 202
2024
Q2
$1.88M Buy
9,557
+75
+0.8% +$15.5K 0.06% 213
2024
Q1
$2.04M Buy
+9,482
New +$1.99M 0.06% 207

Other funds holding CME

Carnegie Investment Counsel's CME Position: Q2 2026 in Review

Carnegie Investment Counsel reduced its CME Group (CME) stake by 1.7% in Q2 2026, selling an estimated $774K and leaving 159,681 shares worth $33.5M. The position accounts for 0.67% of the portfolio, ranked #40.

Carnegie Investment Counsel first reported a position in CME in Q1 2024 and has held it in 10 quarters since. The position peaked at $45.7M in Q1 2026. 956 funds tracked by Wall St. Rank hold CME as of Q2 2026.

  • Carnegie Investment Counsel held 159,681 shares of CME Group worth $33.5M as of Q2 2026.
  • Carnegie Investment Counsel sold 2,797 CME Group shares in Q2 2026, an estimated $774K.
  • CME Group made up 0.67% of Carnegie Investment Counsel's portfolio in Q2 2026, its #40 holding.
  • Carnegie Investment Counsel first reported a position in CME Group in Q1 2024 and has held it in 10 quarters since.
  • Carnegie Investment Counsel's CME Group position peaked at $45.7M in Q1 2026.
  • 956 funds tracked by Wall St. Rank held CME Group as of Q2 2026.

Based on Carnegie Investment Counsel's 13F filing for Q2 2026, filed 30 Jul 2026.